AIMS/HYPOTHESIS: The Modification of Diet in Renal Disease (MDRD) equation has recognised limitations when using estimated GFR in persons at risk of chronic kidney disease. Equations based on cystatin C provide an alternative method. We compared performance of the MDRD equation with a selection of cystatin C-based formulae for estimation of GFR in normoalbuminuric patients with type 2 diabetes. METHODS: Estimated GFR was calculated using the MDRD equation and the cystatin C formulae proposed by several investigator teams. Isotopic GFR was measured using plasma clearance of (51)Cr-EDTA. RESULTS: We studied 106 participants, of whom 83 (78%) were men with the following characteristics, mean (SD): age 61 (9) years, HbA(1c) 7.10 (1.27)%, creatinine 89.0 (12.7) micromol/l, cystatin C 0.859 (0.234) mg/l and isotopic GFR 104.5 (20.1) ml min(-1) 1.73 m(-2). MDRD estimated GFR was 77.4 (13.6) ml min(-1) 1.73 m(-2) (p < 0.05 for difference from isotopic GFR). Cystatin C-based calculations of estimated GFR were: Perkins 124.5 (31.8), Rule 90.0 (30.0), Stevens (age) 96.0 (30.4) and Stevens (creatinine) 85.6 (19.0) ml min(-1) 1.73 m(-2) (p < 0.05 for difference with isotopic GFR). For Arnal's, MacIsaac's and Tan's formulae cystatin-C estimated GFR were 101.7 (34.8), 102.1 (27.0) and 101.6 (27.8) ml min(-1) 1.73 m(-2), respectively (p = NS for difference with isotopic GFR). Cystatin C-based formulae were less biased and, with the exception of Perkins' formula, more accurate to within 10% of isotopic GFR than MDRD. CONCLUSIONS/ INTERPRETATION: Performance of cystatin C equations was superior to MDRD in normoalbuminuric patients with type 2 diabetes. These results support further evaluation of cystatin C for estimation of GFR in persons at risk of chronic kidney disease.
AIMS/HYPOTHESIS: The Modification of Diet in Renal Disease (MDRD) equation has recognised limitations when using estimated GFR in persons at risk of chronic kidney disease. Equations based on cystatin C provide an alternative method. We compared performance of the MDRD equation with a selection of cystatin C-based formulae for estimation of GFR in normoalbuminuric patients with type 2 diabetes. METHODS: Estimated GFR was calculated using the MDRD equation and the cystatin C formulae proposed by several investigator teams. Isotopic GFR was measured using plasma clearance of (51)Cr-EDTA. RESULTS: We studied 106 participants, of whom 83 (78%) were men with the following characteristics, mean (SD): age 61 (9) years, HbA(1c) 7.10 (1.27)%, creatinine 89.0 (12.7) micromol/l, cystatin C 0.859 (0.234) mg/l and isotopic GFR 104.5 (20.1) ml min(-1) 1.73 m(-2). MDRD estimated GFR was 77.4 (13.6) ml min(-1) 1.73 m(-2) (p < 0.05 for difference from isotopic GFR). Cystatin C-based calculations of estimated GFR were: Perkins 124.5 (31.8), Rule 90.0 (30.0), Stevens (age) 96.0 (30.4) and Stevens (creatinine) 85.6 (19.0) ml min(-1) 1.73 m(-2) (p < 0.05 for difference with isotopic GFR). For Arnal's, MacIsaac's and Tan's formulae cystatin-C estimated GFR were 101.7 (34.8), 102.1 (27.0) and 101.6 (27.8) ml min(-1) 1.73 m(-2), respectively (p = NS for difference with isotopic GFR). Cystatin C-based formulae were less biased and, with the exception of Perkins' formula, more accurate to within 10% of isotopic GFR than MDRD. CONCLUSIONS/ INTERPRETATION: Performance of cystatin C equations was superior to MDRD in normoalbuminuric patients with type 2 diabetes. These results support further evaluation of cystatin C for estimation of GFR in persons at risk of chronic kidney disease.
Authors: R J Macisaac; C Tsalamandris; M C Thomas; E Premaratne; S Panagiotopoulos; T J Smith; A Poon; M A Jenkins; S I Ratnaike; D A Power; G Jerums Journal: Diabetologia Date: 2006-05-03 Impact factor: 10.122
Authors: Bruce A Perkins; Robert G Nelson; Betsy E P Ostrander; Kristina L Blouch; Andrzej S Krolewski; Bryan D Myers; James H Warram Journal: J Am Soc Nephrol Date: 2005-03-23 Impact factor: 10.121
Authors: Anna Köttgen; Elizabeth Selvin; Lesley A Stevens; Andrew S Levey; Frederick Van Lente; Josef Coresh Journal: Am J Kidney Dis Date: 2008-03 Impact factor: 8.860
Authors: Lesley A Stevens; Josef Coresh; Christopher H Schmid; Harold I Feldman; Marc Froissart; John Kusek; Jerome Rossert; Frederick Van Lente; Robert D Bruce; Yaping Lucy Zhang; Tom Greene; Andrew S Levey Journal: Am J Kidney Dis Date: 2008-03 Impact factor: 8.860
Authors: Marie-Christine Beauvieux; Françoise Le Moigne; Catherine Lasseur; Christelle Raffaitin; Caroline Perlemoine; Nicole Barthe; Philippe Chauveau; Christian Combe; Henri Gin; Vincent Rigalleau Journal: Diabetes Care Date: 2007-05-29 Impact factor: 19.112
Authors: James B Wetmore; Robyn A Honea; Eric D Vidoni; Ammar Almehmi; Jeffrey M Burns Journal: Nephrol Dial Transplant Date: 2010-11-23 Impact factor: 5.992
Authors: Christopher M Ryan; Puneet Souda; Frederic Halgand; David T Wong; Joseph A Loo; Kym F Faull; Julian P Whitelegge Journal: J Am Soc Mass Spectrom Date: 2010-02-01 Impact factor: 3.109
Authors: Ian H de Boer; Wanjie Sun; Patricia A Cleary; John M Lachin; Mark E Molitch; Bernard Zinman; Michael W Steffes Journal: J Am Soc Nephrol Date: 2013-12-05 Impact factor: 10.121
Authors: Willemijn L Eppenga; Cornelis Kramers; Hieronymus J Derijks; Michel Wensing; Jack F M Wetzels; Peter A G M De Smet Journal: PLoS One Date: 2015-03-05 Impact factor: 3.240
Authors: Natalia Nowak; Magdalena Szopa; Gaya Thanabalasingham; Tim J McDonald; Kevin Colclough; Jan Skupien; Timothy J James; Beata Kiec-Wilk; Elzbieta Kozek; Wojciech Mlynarski; Andrew T Hattersley; Katharine R Owen; Maciej T Malecki Journal: Acta Diabetol Date: 2012-02-19 Impact factor: 4.280